Please use this identifier to cite or link to this item:
Title: Faster Blood Flow Rate Does Not Improve Circuit Life in Continuous Renal Replacement Therapy: A Randomized Controlled Trial.
Austin Authors: Fealy, Nigel G ;Aitken, Leanne;du Toit, Eugene;Lo, Serigne;Baldwin, Ian C 
Affiliation: Melanoma Institute Australia, Research and Biostatistics group, Wollstonecraft, NSW, Australia
Intensive Care Unit, Princess Alexandra Hospital, Brisbane, QLD, Australia
School of Health Sciences, City, University of London, London, United Kingdom
Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia
School of Nursing and Midwifery, Griffith University, Brisbane, QLD, Australia
School of Nursing and Midwifery, Deakin University, Melbourne, Victoria, Australia
Centre for Health Practice Innovation, Griffith Health Institute, Griffith University, Brisbane, QLD, Australia
School of Medical Science, Griffith University, Gold Coast, Sydney, QLD, Australia
Issue Date: Oct-2017
Publication information: Critical Care Medicine 2017; 45(10): e1018-e1025
Abstract: To determine whether blood flow rate influences circuit life in continuous renal replacement therapy. Prospective randomized controlled trial. Single center tertiary level ICU. Critically ill adults requiring continuous renal replacement therapy. Patients were randomized to receive one of two blood flow rates: 150 or 250 mL/min. The primary outcome was circuit life measured in hours. Circuit and patient data were collected until each circuit clotted or was ceased electively for nonclotting reasons. Data for clotted circuits are presented as median (interquartile range) and compared using the Mann-Whitney U test. Survival probability for clotted circuits was compared using log-rank test. Circuit clotting data were analyzed for repeated events using hazards ratio. One hundred patients were randomized with 96 completing the study (150 mL/min, n = 49; 250 mL/min, n = 47) using 462 circuits (245 run at 150 mL/min and 217 run at 250 mL/min). Median circuit life for first circuit (clotted) was similar for both groups (150 mL/min: 9.1 hr [5.5-26 hr] vs 10 hr [4.2-17 hr]; p = 0.37). Continuous renal replacement therapy using blood flow rate set at 250 mL/min was not more likely to cause clotting compared with 150 mL/min (hazards ratio, 1.00 [0.60-1.69]; p = 0.68). Gender, body mass index, weight, vascular access type, length, site, and mode of continuous renal replacement therapy or international normalized ratio had no effect on clotting risk. Continuous renal replacement therapy without anticoagulation was more likely to cause clotting compared with use of heparin strategies (hazards ratio, 1.62; p = 0.003). Longer activated partial thromboplastin time (hazards ratio, 0.98; p = 0.002) and decreased platelet count (hazards ratio, 1.19; p = 0.03) were associated with a reduced likelihood of circuit clotting. There was no difference in circuit life whether using blood flow rates of 250 or 150 mL/min during continuous renal replacement therapy.
DOI: 10.1097/CCM.0000000000002568
Journal: Critical Care Medicine
PubMed URL: 28658026
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.